The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution ...

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment. The first-line treatment of locally advanced metastatic non-small cell ...

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and ...

SINGAPORE, Dec. 8, 2025First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, ...

Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...

“By combining the multi-targeted mechanism of amivantamab with lazertinib, a central nervous system penetrant third-generation tyrosine kinase inhibitor, we are advancing a chemotherapy-free regimen ...

BEERSE, Belgium--(BUSINESS WIRE)--FOR EMEA TRADE AND MEDICAL MEDIA ONLY. Not for distribution to UK, Italy and Benelux based media. The Janssen Pharmaceutical Companies of Johnson & Johnson today ...

“The survival curve demonstrates that amivantamab plus lazertinib can help patients live longer compared to osimertinib monotherapy, and suggests the benefit keeps growing over time,” said trial ...

BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new analyses from the Phase 3 MARIPOSA study showing that first-line ...

CHMP Recommends RYBREVANT® (Amivantamab) In Combination With LAZCLUZE® (Lazertinib) For The First-Line Treatment Of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. The amivantamab plus ...